Who
Dinesh P.H. D. Patel V
President and CEO
Company insider
Files Form 4 as: President and CEO, Protagonist Therapeutics.
In numbers
- Trades disclosed
- 194
- Buys
- 1
- Sells
- 31
- Bought
- $169K
- Sold
- $135.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Oct 2016
- Last trade
- 10 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 10 Sep 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,278 at $0.00 | filing |
| 10 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $157K7,278 at $21.58 | filing |
| 10 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M7,278 at $144.10 | filing |
| 10 Sep 2026filed 10 Sep 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,278 at $0.00 | filing |
| 10 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $157K7,278 at $21.58 | filing |
| 10 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M7,278 at $144.10 | filing |
| 9 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.4M63,548 at $21.58 | filing |
| 9 Sep 2026filed 10 Sep 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —63,548 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $9.3M63,548 at $146.18 | filing |
| 9 Sep 2026filed 10 Sep 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —63,548 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.4M63,548 at $21.58 | filing |
| 9 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $9.3M63,548 at $146.18 | filing |
| 8 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.2M54,174 at $21.58 | filing |
| 8 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.9M54,174 at $145.87 | filing |
| 8 Sep 2026filed 10 Sep 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —54,174 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —54,174 at $0.00 | filing |
| 8 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.2M54,174 at $21.58 | filing |
| 8 Sep 2026filed 10 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.9M54,174 at $145.87 | filing |
| 3 Sep 2026filed 8 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code G | —510 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code G | —510 at $0.00 | filing |
News
Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)PTGX · dailypolitical.com · 22 Oct 2026Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Dinesh P.H. D. Patel V; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.